Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy

CD19 chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, the cytokine release syndrome (CRS) was presented in most patients as common toxicity and severe CRS (sCRS) characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Wen-Jie, Qiu, Yan, Li, Ming-Hao, Chen, Li-Yun, Li, Yan-Yan, Yu, Jing-Qiu, Kang, Li-Qing, Sun, Ai-Ning, Wu, De-Pei, Yu, Lei, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464804/
https://www.ncbi.nlm.nih.gov/pubmed/36105799
http://dx.doi.org/10.3389/fimmu.2022.922212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464804/
https://www.ncbi.nlm.nih.gov/pubmed/36105799
http://dx.doi.org/10.3389/fimmu.2022.922212

Ejemplares similares